Novo Is Suing Lilly Over a Head-to-Head Trial Lilly Won, Arguing the Result Went Stale
Novo Nordisk filed a Lanham Act suit over Lilly’s Zepbound ads, arguing a genuine head-to-head result became misleading once a higher Wegovy dose launched.
Wegovy
Dutch Healthcare Institute Limits Early Access to Obesity Drugs Amid Cost and Evidence Concerns
The Dutch Healthcare Institute is taking a cautious, phased approach to new obesity drugs, limiting access to patients with the highest disease burden. The move reflects concerns about evidence gaps, cost-effectiveness, and the growing pressure obesity treatments could place on the national healthcare budget.